Brief: Bausch + Lomb To Discontinue BL1107 Eye Drop Development For Glaucoma
09/07/2026 22:02
BRIEF-Bausch + Lomb To Discontinue BL1107 Eye Drop Development For Glaucoma July 9 (Reuters) - Bausch + Lomb Corp BLCO.TO:
ANNOUNCES PHASE 2 RESULTS FOR GLAUCOMA NEUROPROTECTIVE CANDIDATE
PHASE 2 STUDY FOR BL1107 DOES NOT MEET PRIMARY ENDPOINT
TO DISCONTINUE BL1107 EYE DROP DEVELOPMENT FOR GLAUCOMA
TO BEGIN CLINICAL TRIALS FOR SUSTAINED-RELEASE IMPLANT FOR GA IN 2028
BL1107 PHASE 2 STUDY DOES NOT ACHIEVE KEY SECONDARY VISUAL FUNCTION ENDPOINTS
BL1107 PHASE 2 STUDY SHOWS NO NEW SAFETY SIGNALS
Source text: ID:nBw8W4Nvta
Further company coverage: BLCO.TO
((Reutersbriefs@thomsonreuters.com;))
Recent news on Bausch + Lomb
See all newsBausch + Lomb CEO Saunders departs, Chairman Appio named interim chief (updated)
Brief: Bausch + Lomb And Bausch Health Announce Appointment Of Thomas J. Appio As Interim Bausch + Lomb CEO, Expect To Raise Full-Year 2026 Guidance
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief
Brief: US FDA sent warning letter to Bausch & Lomb on September 4
Brief: Bausch + Lomb Announces European CE Mark Approval Of Seelyra™ Femtosecond Laser